Medical Disclaimer
Last updated May 1, 2026.
Educational Use Only
The information on GLP Insights is provided for general educational purposes only. It is not intended as, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified healthcare provider with any questions you may have regarding a medical condition or medication.
No Doctor-Patient Relationship
Reading GLP Insights does not create a doctor-patient relationship, nurse-patient relationship, or any other clinical relationship between you and GLP Insights or its editors. We are not licensed healthcare providers. We do not diagnose, prescribe, dispense, or monitor treatment. We synthesize publicly available medical literature for educational purposes.
GLP-1 Medications Are Prescription Drugs
GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and others — are prescription medications. They have serious potential side effects, drug interactions, and contraindications. They are not appropriate for everyone.
The FDA has issued boxed warnings and ongoing safety communications regarding these medications. The FDA has also issued warnings about counterfeit and unverified compounded versions sold outside the regulated pharmacy system. Speak with a licensed clinician before starting, changing, or stopping any GLP-1 medication.
Individual Results Vary
Weight loss outcomes, blood-sugar improvements, and other results we cite — such as the approximately 15% mean body-weight reduction with semaglutide 2.4 mg in the STEP-1 trial or the approximately 22% with tirzepatide 15 mg in SURMOUNT-1 — are averages from published clinical trials. They are not promises of what any individual will experience. Outcomes depend on medication, dosage, duration of treatment, adherence, lifestyle factors, and individual physiology.
Emergencies
If you experience any of the following while taking a GLP-1 medication, contact your prescriber or seek emergency care immediately:
- Severe persistent abdominal pain (possible pancreatitis)
- Persistent vomiting or inability to keep fluids down
- Yellowing of skin or eyes (jaundice)
- Severe difficulty breathing, swelling of the face/tongue/throat (anaphylaxis)
- Severe hypoglycemia (especially if also taking insulin or sulfonylureas)
- Significant vision changes
- Thoughts of self-harm
For medical emergencies, call 911 (US) or your local emergency number immediately.
Contraindications
Do not take GLP-1 receptor agonists if you have any of the following without explicit clinical guidance:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
- History of pancreatitis
- Severe gastrointestinal motility disorders such as gastroparesis
- Pregnancy or planning pregnancy within two months
- Known hypersensitivity to the medication
Compounded Medications
Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by state-licensed compounding pharmacies for individual patients with a prescription. Federal law permits compounding under specific conditions, generally during periods of FDA-listed shortage. Quality and safety depend on the compounding pharmacy's accreditation and sourcing. Only use compounded GLP-1 prescribed by a US-licensed clinician and dispensed by an accredited US pharmacy.
Information Currency
The GLP-1 medical and regulatory landscape changes frequently. FDA shortage status, approved indications, coverage rules, and pricing can shift quickly. We update each page monthly and display a last-updated date. Always verify time-sensitive details (such as current FDA shortage status or current pricing) with primary sources before making medical or financial decisions.
Limitation of Liability
GLP Insights, its editors, and its affiliates make no warranties about the completeness, reliability, or accuracy of any information on this site. Any action you take based on information from this site is strictly at your own risk. We are not liable for losses or damages arising from the use of this site or reliance on its content.